The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Abbvie; Cardinal Health; Clarity Pharmaceuticals; Convergent Therapeutics; Fusion Pharmaceuticals; Lilly; POINT Biopharma; Ratio Therapeutics; Telix Pharmaceuticals; United Health Group
Honoraria - Lantheus Medical Imaging
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; ARTbio; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Bristol-Myers Squibb; Clarity Pharmaceuticals; Clovis Oncology; EMD Serono; Fusion Pharmaceuticals; Hengrui Therapeutics; Isotopen Technologien; Janssen; MacroGenics; Merck; Morphimmune; Noria Therapeutics; Northstar Medical radioisotopes; Novartis; Noxopharm; Pfizer; POINT Biopharma; Ratio Therapeutics; Sanofi; Telix Pharmaceuticals; Tempus; Tessa Therapeutics; Theragnostics
Research Funding - Advanced Accelerator Applications (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Constellation Pharmaceuticals (Inst); Endocyte (Inst); Invitae (Inst); Janssen (Inst); Lantheus Medical Imaging (Inst); Merck (Inst); Progenics (Inst); Sanofi (Inst); Sotio (Inst)
Patents, Royalties, Other Intellectual Property - Koochekpour, Sartor AO, inventors. Saposin C and receptors as targets for treatment of benign and malignant disorders. US patent awarded January 23, 2007 (patent no. 7,166,691)
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Bayer; JJ Innovative Medicine; Lantheus Medical Imaging; Progenics; Sanofi
A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC).
 
Michael J. Morris
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Ambrx; Arvinas; AstraZeneca; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Clarity Pharmaceuticals; Convergent Therapeutics; Core Medica; Curium Pharma; Daiichi; Exelixis; Flare Therapeutics; Fusion Pharmaceuticals; ITM Isotope Technologies Munich; Lantheus Medical Imaging; Mashup Media; Pfizer; POINT Biopharma; Progenics; Telix Pharmaceuticals; Transtherabio; Z-Alpha
Research Funding - Astellas Pharma (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Janssen (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; APCCC; AstraZeneca; Memorial Sloan-Kettering Cancer Center
Other Relationship - Novartis
(OPTIONAL) Uncompensated Relationships - Amgen; Amgen; Bayer; Janssen Oncology; Novartis
 
Jeffrey Y.C. Wong
Consulting or Advisory Role - Blue Earth Diagnostics; Telix Pharmaceuticals
Research Funding - Accuray (Inst); Reflexion Medical (Inst); Varian Medical Systems (Inst)
 
Luke Nordquist
No Relationships to Disclose
 
Russell Zelig Szmulewitz
Honoraria - Astellas Pharma; Pfizer/Astellas
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Eisai; Exelixis; Janssen Oncology; Merck; Novartis; Pfizer; Sanofi
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Harpoon therapeutics (Inst); Janssen Oncology (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Plexxikon (Inst); Progenics (Inst)
Patents, Royalties, Other Intellectual Property - Patent licensed by University of Chicago of which I am co-inventor to Corcept Therapeutics for combination AR/GR inhibition in prostate cancer
Travel, Accommodations, Expenses - Corcept Therapeutics
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Edward F. Attiyeh
Employment - Janssen Research & Development
 
Steven I Max
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Chaitanya R. Divgi
Consulting or Advisory Role - Janssen Research & Development; SpectronRX, Inc
 
Daniel Patricia
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Yu Cao
Employment - Janssen Research & Development
 
Xiang Li
Employment - Janssen Research & Development
 
Alex Yu
Employment - Janssen Research & Development
 
Karen Urtishak
Employment - Janssen Research & Development
 
Josh David Lauring
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Oliver Sartor
No Relationships to Disclose